Comhony Biotech

Kanghong Biotech (often referred to as Comhony Biotech in international filings) is a prominent Chinese biopharmaceutical company and a key subsidiary of the Kanghong Pharmaceutical Group. The company is best known for the development of Conbercept (Lumitin), a proprietary recombinant fusion protein that inhibits VEGF and PIGF, which has become a leading treatment for retinal diseases in China. Kanghong Biotech focuses on high-end biologics, utilizing its expertise in protein engineering and its emerging gene therapy platform to address unmet needs in ophthalmology and oncology. With major R&D and manufacturing hubs in Chengdu and Beijing, the company is actively expanding its clinical pipeline to include next-generation treatments for solid tumors and CNS disorders. Its flagship product, Conbercept, represents one of the most successful domestically developed biologics in the Chinese market.